Stevens Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $240K | Buy |
+311
| New | +$238K | 0.04% | 200 |
|
|
2025
Q4 | – | Sell |
-1,409
| Closed | -$792K | – | 310 |
|
|
2025
Q3 | $792K | Buy |
+1,409
| New | +$797K | 0.11% | 126 |
|
|
2024
Q4 | – | Sell |
-452
| Closed | -$475K | – | 370 |
|
|
2024
Q3 | $475K | Buy |
+452
| New | +$503K | 0.07% | 120 |
|
|
2024
Q1 | – | Sell |
-418
| Closed | -$367K | – | 345 |
|
|
2023
Q4 | $367K | Buy |
+418
| New | +$344K | 0.09% | 184 |
|
|
2023
Q2 | – | Sell |
-1,008
| Closed | -$828K | – | 297 |
|
|
2023
Q1 | $828K | Buy |
1,008
+230
| +30% | +$173K | 0.21% | 71 |
|
|
2022
Q4 | $561K | Sell |
778
-73
| -9% | -$53.9K | 0.35% | 49 |
|
|
2022
Q3 | $586K | Buy |
851
+152
| +22% | +$95.7K | 0.38% | 49 |
|
|
2022
Q2 | $413K | Buy |
+699
| New | +$454K | 0.29% | 59 |
|
|
2022
Q1 | – | Sell |
-4,407
| Closed | -$2.78M | – | 294 |
|
|
2021
Q4 | $2.78M | Buy |
4,407
+1,745
| +66% | +$1.07M | 0.64% | 41 |
|
|
2021
Q3 | $1.61M | Buy |
+2,662
| New | +$1.65M | 0.68% | 34 |
|
|
2021
Q2 | – | Sell |
-427
| Closed | -$202K | – | 222 |
|
|
2021
Q1 | $202K | Buy |
+427
| New | +$208K | 0.11% | 117 |
|
|
2020
Q4 | – | Sell |
-18,098
| Closed | -$10.1M | – | 212 |
|
|
2020
Q3 | $10.1M | Buy |
+18,098
| New | +$11M | 3.76% | 5 |
|
|
2019
Q4 | – | Sell |
-3,283
| Closed | -$911K | – | 764 |
|
|
2019
Q3 | $911K | Sell |
3,283
-28,955
| -90% | -$8.57M | 0.08% | 245 |
|
|
2019
Q2 | $10.1M | Buy |
32,238
+31,519
| +4,384% | +$10.5M | 0.45% | 50 |
|
|
2019
Q1 | $295K | Buy |
+719
| New | +$296K | 0.01% | 577 |
|
|
2018
Q1 | – | Sell |
-18,613
| Closed | -$7M | – | 944 |
|
|
2017
Q4 | $7M | Buy |
+18,613
| New | +$7.54M | 0.27% | 115 |
|
|
2016
Q3 | – | Sell |
-7,364
| Closed | -$2.57M | – | 1105 |
|
|
2016
Q2 | $2.57M | Buy |
+7,364
| New | +$2.84M | 0.1% | 254 |
|
|
2016
Q1 | – | Sell |
-15,022
| Closed | -$8.15M | – | 1069 |
|
|
2015
Q4 | $8.15M | Buy |
15,022
+9,736
| +184% | +$5.28M | 0.32% | 90 |
|
|
2015
Q3 | $2.46M | Buy |
+5,286
| New | +$2.84M | 0.11% | 198 |
|
|
2014
Q3 | – | Sell |
-50,749
| Closed | -$14.3M | – | 1207 |
|
|
2014
Q2 | $14.3M | Buy |
+50,749
| New | +$15M | 0.38% | 69 |
|
|
2014
Q1 | – | Sell |
-25,429
| Closed | -$7M | – | 1274 |
|
|
2013
Q4 | $7M | Buy |
+25,429
| New | +$7.31M | 0.21% | 129 |
|
|
2013
Q3 | – | Sell |
-21,937
| Closed | -$4.93M | – | 1179 |
|
|
2013
Q2 | $4.93M | Buy |
+21,937
| New | +$5.11M | 0.16% | 169 |
|
Other funds holding REGN
VCM
N
Stevens Capital Management's REGN Position: Q1 2026 in Review
Stevens Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 311 shares worth $240K. The stake represents 0.04% of the portfolio and ranks #200 among its holdings. This is a return to the name: Stevens Capital Management previously reported a position in REGN as recently as Q3 2025.
Stevens Capital Management first reported a position in REGN in Q2 2013 and has held it in 22 quarters since. The position peaked at $14.3M in Q2 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Stevens Capital Management held 311 shares of Regeneron Pharmaceuticals worth $240K as of Q1 2026.
- Regeneron Pharmaceuticals was a new Stevens Capital Management position in Q1 2026.
- Regeneron Pharmaceuticals made up 0.04% of Stevens Capital Management's portfolio in Q1 2026, its #200 holding.
- Stevens Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
- Stevens Capital Management's Regeneron Pharmaceuticals position peaked at $14.3M in Q2 2014.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.